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Abstract Synthetic biology is currently one of the most
debated emerging biotechnologies. The societal assessment
of this technology is primarily based on contributions by
scientists and policy makers, who focus mainly on technical
challenges and possible risks. While public dialogue is
given, it is yet rather limited. This study explores public
debates concerning synthetic biology based on a focus group
study with citizens from Austria and Germany and contex-
tualises the analysed public views with content from policy
reports and previous empirical studies on public engage-
ment. The findings suggest that discussants favoured a
gradual implementation process of synthetic biology, which
is receptive to questions about the distribution of possible
benefits. The discussed topics correspond inmanywayswith
content frompolicy reports and former investigations, yet the
emphasis of the discussions was different for many aspects.
Keywords Emerging biotechnologies  Public
engagement  Synthetic biology  Bioethics
Introduction
Emerging biotechnologies operate at the threshold of
technological innovation and public expectations. They
have gained growing attention in the recent decades as
scientists and policy maker likewise evaluate them as
promising for different areas, including food and energy
production, pharmaceutical industry or intellectual capital
(Nuffield Council on Bioethics 2012; BBSRC and EPSRC
2011). One of the most frequently debated emerging
biotechnologies is synthetic biology (SB). SB is widely
understood as an umbrella term for a range of scientific
practices bringing together scientists and engineers who
either seek to develop novel bio-bricks, proto-cells or
simple life-forms from scratch (bottom-up), or fundamen-
tally modify existing organisms by implementing synthetic
genes or proteins (top-down) (Singh 2014). The general
objective is to generate and assemble functional modular
components for the development of novel applications and
processes within fields like agriculture, energy production
and medicine. Beyond the first achievements within a
synthetic version of the antimalarial compound Artemisi-
nin (Carothers 2013) there are several SB-projects, which
aim at contributing to the vaccine development for com-
municable diseases such as the Human Immunodefi-
ciency—(Rerks-Ngarm et al. 2009; Hansen et al. 2013) or
the Hepatitis C virus (Liang 2013). Beyond such scientific
developments from the medical sector, SB is also supposed
to offer novel opportunities for the creation of new
industries with profound economic implications for the
major economies (Klo¨ck 2015).
Beside the envisioned benefits of SB, there are however
several scientific, legal as well as ethical uncertainties.
These are associated with the development of synthetic
life, cells or genomes, and regarding their potential impact
on the environment, biological diversity as well as human
health (Scientific Committee on Health and Environmental
Risks et al. 2015). Whereas some stakeholder rate the
existing legal regulations (especially the EU Directives
2001/18 EC and 2009/41/EC) to sufficiently cover the
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current research action (Bar Yam et al. 2012; OECD 2014),
other claim a need for an on going focus on biosafety and
biosecurity issues (German Ethics Council 2014) as well as
a focus on a possible lack of distinct laws for issues like
ownership or trans-nationality (The US National Academy
of Science 2013; BIOS 2011). There are furthermore
technical and governance challenges that gain ongoing
awareness, peculiarly concerning the possible ecological or
health effects (Dana et al. 2012). Yet there is no clear
vision of an appropriate governance frame regarding SB.
Thus, one of the most urgent desiderata is to develop an
innovative and sustainable governance frame in order to
balance this new emerging biotechnology at a very early
stage (BIOS 2011).
Nevertheless, there are several policy and governance
recommendations on SB by different commissions and
agencies published within the last 5 years. In general such
recommendations advice to proceed research while making
risks transparent (Nuffield Council on Bioethics 2012). In
spite of all differences, three common topics can be iden-
tified amongst these reports. A frequently issue is (A) the
question of a well-adjusted risk assessment. Regarding the
aspect of bio-safety, questions on release, exchange with
natural systems as well as unknown and possibly precari-
ous future developments are discussed. Bio-security is
most commonly related to intended misuse of bioscience
for criminal intents or bio-terrorism (European Commis-
sion 2010; European Academies Science Advisory Council
2010; International Risk Governance Council 2010; Acat-
ech 2012; Health and Security Executive 2012). Beside
security questions the reports point out (B) the importance
of intellectual and economic property issues. Thereby
questions on the distribution of economic benefits (OECD
2010, 2014) or intellectual and legal ownership (European
Group on Ethics 2009; US National Academy of Science
2013) are discussed. A third frequently discussed issue is
(C) the question whether certain criteria must be met in
order to call a governance strategy solid and responsible.
The US National Academy of Science (2013), for example,
published a summary report of an international symposium
series that addressed, amongst other issues, regulatory
challenges associated with the fluid boundaries, multiple
applications and the yet unknown future of the field. Fur-
thermore, the inclusiveness and the modes of engagement
with various stakeholder are discussed. The inclusion and
connection of stakeholder for sustainable governance
includes, within most reports, to integrate the views and
values of citizens and to therefore act in their interest while
intensifying public dialogue (Presidential Commission for
the Study of Bioethical Issues 2010). A report by BIOS
(2011) attests the fragmentation of stakeholder and
demands a stronger focus on cross-borderness. Thus, a
common and sustainable governance strategy must
integrate the views and values of different publics. It is
therefore of utmost importance to foster and intensify the
public-science dialogue.
Yet, including publics in scientific and technological
innovation processes has always been controversial. In the
80es and early 90es of the last century, it was merely
common sense that increasing information for (unin-
formed) publics will likely increase their acceptance of
science (deficit paradigm). Different studies have however
shown that publics develop different forms of expertise and
that views of ‘‘experts’’ are only one valid viewpoint
amongst others (Wynne 1996; Epstein 1996). Therefore, a
new dialogue paradigm emerged that embraces concepts
like engagement (House of Lords Select Committee on
Science and Technology 2000), mutual inclusiveness
(Prainsack 2014), and responsible research and innovation
(Von Schomberg 2011). The latter is one leading principle
for emerging biotechnologies in Europe which emphati-
cally promotes an interactive and transparent implemen-
tation of technologies that likewise includes stakeholders,
professionals and citizens (European Commission 2011;
Von Schomberg 2011). Yet, including citizens in the
governance of an emerging technology may occur in dif-
ferent ways, a common strategy within the European
Horizon 2020 funding programme is to deliberatively
engage (representatively polled or purposively selected)
citizens in events, debates or interviews. Dependent on the
methodology, different conceptions of ‘‘publics’’ lead these
endeavours. While polls address publics foremost as all
citizens within a political space (Law 2009), discursive
qualitative methods like focus groups construct publics as
temporary groups of interested or affected citizens (Dewey
2007).
Public engagement strategies in the field of emerging
biotechnologies have not only been intensified during the
last decades, Hansen and Metzler (2012) go as far as
claiming the identification of a shift from a reactive to a
prospective (anticipated) approach of public engagement
within new technologies. Thus, different civil society
organisations, stakeholder and institutions aim to generate
public engagement at a very early stage of the innovation
processes rather than to educate people for the sake of
greater acceptance of technology (Acatech 2012). Whilst
there exist numerous studies on public perceptions of dif-
ferent emerging biotechnologies, those that focus on SB are
still few in number.
A Eurobarometer survey shows that representatively
polled Europeans are divided in their attitudes towards the
question whether the public should be actively involved in
the governance of science and technology or if the provi-
sion of information is sufficient (European Commission
2013). The same Eurobarometer study shows that Euro-
peans generally express a favourable approach towards
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science and technology. Nevertheless, most citizens say to
have no knowledge about SB in particular (European
Commission 2010; Pauwels 2009). The potential for public
conflict with SB is thus still up for debate (Torgersen and
Hampel 2012). Some scholars claim that most people have
no interest in these technologies and that its potential for
conflict is therefore overestimated. The special exhibition
Gen-Welten (gene-worlds) that was launched in 1998 in
four German-speaking cities, for example, gained much
less interest and had much less visitors than expected
(Schmidt 2001).
Many authors conclude that people make sense of SB
based on former experiences with other biotechnologies
(Kronberger et al. 2012; Torgersen and Schmidt 2013).
While different empirical studies show that both, rejection
and support, are given; supportive attitudes are mainly
expressed concerning medical applications (BBSRC 2012;
Kronberger et al. 2012; Pauwels 2009). However most
stakeholder reason that citizens mainly take notice of
personal risks rather than consumer benefits (Acatech
2012). This statement is backed up by empirical findings
from another Eurobarometer study in which respondents
expressed their wish for more knowledge of risks rather
than of benefits (European Commission 2010).
However, a quantitative study conducted by the Hart
Research Associates (2013) in the US reports a balanced
perception of risks and benefits of SB by the public. The same
study suggests that more information on SB might even for-
titude critical attitudes. Once respondents were given more
information, they tended to perceive risks more dominantly.
However, in the ratio of two to one, Americans believe SB
should be allowed to move forward rather than to be banned,
which suggests a substantial support for this kind of research
in theUS. Indetail, respondents expressedmost concern about
bio-warfare (28 %), the creation of life as moral rupture
(27 %), possible negative health effects (20 %) and dangers
for the environment (17 %). A related focus group study by
theHartResearchAssociates (2014) highlights oncemore that
people perceive both, risks and benefits, while the latter are
more dominant in conjunction with medical applications.
During the discussions, the unforeseen and unintended con-
sequences were the major issues rather than unintended usage
like bio-warfare or bio-terrorism.
Being polled about concerns regarding SB, people from
the EU-27 mostly emphasised the speed of change,
unforeseen side effects and potential terrorist usage of new
technologies from a list of different issues (European
Commission 2013). A large qualitative and quantitative
study by the German Institut fu¨r Demoskopie Allensbach
and Leopoldina German National Academy of Sciences
(Leopoldina 2015) stresses that Germans perceive SB as
complex, distant issue, which is evaluated along perceived
risks and benefits for particular fields of applications.
These studies about public perceptions of SB present a
first glance unto this broad topic. We therefore set up a
focus group study in order to explore and analyse how
German and Austrian citizens perceive different applica-
tions that can be located at the gateway of Genetic Engi-
neering and SB. Therefore, the study is interested in the
reasoning patterns and to scrutinize public understandings
of meaningful governance frameworks for this technology.
Research agenda and methodology
The presupposition at the beginning of the investigation
was constituted by the assumption that most people have
not heard much details about SB. This presumption is also
backed by a Eurobarometer study (European Commission
2010) that revealed that most Europeans said to have not
heard of emerging biotechnologies so far. While any
engagement with groups of citizens necessarily had to
imply an introduction to the field of SB, we still aimed for
an open and explorative approach.
On this basis, we conducted a focus group study in
Erlangen and Nuremberg, Germany, and in Vienna, Austria
to better understand how different groups of citizens per-
ceive and reflect novel scientific practices. These locations
were chosen as former investigations have shown that
people in central European countries like Germany and
Austria express comparably high concerns about emerging
biotechnologies (European Commission 2010) and there-
fore provide a good sample for critical reflections.
Focus groups are discussions of small groups of people
led by a professional moderator and are widely used in the
field of research on public engagement (Bloor et al.
2001).They reveal how members of the public discuss and
reflect certain issues addressed by a moderator. The major
aim is to identify different understandings and shared
patterns of meaning, rather than to produce representative
data on certain populations. We sampled citizens for the
respective focus groups and aimed for homogeneity in
terms of the participants’ age and education, whereas the
overall sample provided a range of people with multiple
socio-demographic backgrounds. The individual groups
therefore consisted either of younger (18–35 years) or
mature/older people (35? years), and respectively either of
people with higher or lower educational level. While many
of our discussants had a high educational status (tertiary
education), groups with people of lower education levels
participated as well. Each discussion group consisted of
about six to eleven people. The sample of all nine groups
together consisted of 37 women and 32 men, whereas the
average age was 39. We recruited a balanced sample of
people with different employment statuses. All individuals
were recruited via online platforms and multiplicator
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persons (snowballing), totalling 69 participants. Each
group session lasted for about one and a half hour
(Table 1).
The discussions were arranged with an open approach,
but with alertness to provide a reliable data set. This means
that all groups followed the same topic guide applied by the
same moderator. Participants were introduced to the field
of emerging biotechnologies with a focus on genetic
engineering and SB. It was explained that all organisms
rely to some extend on a construction plan consisting of
DNA, and that this plan sets a frame for its appearance and
abilities. It was then explained that humans have interfered
with this construction plan for several hundred years by
breeding animals or specific plant types. Novel scientific
practices have provided the opportunity to directly change
or alter existing DNA structures and are therefore capable
to achieve different effects. All groups were then intro-
duced stepwise to three different areas of application,
synthetic (1) fungus, (2) viruses and (3) algae with antici-
pated applications in the respective fields of (1) drug-de-
velopment, (2) agriculture and (3) bio-fuel.
Case (1) is a widely cited example of the synthetically
reproduced active substance Artemisinin that is the vital
ingredient of lots of anti-malaria-drugs (Ro et al. 2006;
Van Noorden 2010; Westfall et al. 2012). During the ses-
sion, focus group participants were explained that a yeast
fungus was genetically modified so that it started to pro-
duce Artemisinin such as the Artemisia Annua plant, and
that this synthetic substance was then reprocessed to anti-
malaria-drugs for clinical trials.
In case (2), participants were told how scientists
experimented in order to synthetically produce viruses with
the aim to affect a certain type of insect, which, from an
agricultural perspective, is considered as being a vermin.
Furthermore, it was claimed that it is anticipated that this
virus will not affect other animals and that it will not be
subject to evolution. Scientists would follow several
approaches using viruses for insect control in agriculture,
ranging from sterilisation to directed mutations (Fu et al.
2007; Son et al. 2006; Szewczyk et al. 2006).
The last case (3) addressed the use of algae-based bio-
fuel production. It was communicated that algae is seen as
a possible alternative to fossil fuels and that scientists aim
to optimise the efficiency by altering the genetic structure
of algae. Strategies include creating plants that depend on
less light or making them produce more oil for refinement
(Service 2011).
In each case we communicated that although the stres-
sed applications and security measures are anticipated aims
by scientists, it is yet not clear whether these aims might be
achieved or if security measures will take full effect.
Regarding each case the discussants were asked about their
thoughts on these specific applications and which societal
and governmental implications they assumed. The groups
were given about 20 min per case to freely discuss their
views. At the end of the discussions, the participants were
asked about the similarities and differences between the
three cases and how the presented technologies should be
governed.
All data was audio-recorded and then transcribed for
further analysis. The study’s aim was furthermore to go
beyond the manifest content of the participants’ statements
and revealing latent structures of meaning (Smithson
2000). We therefore conducted a theoretical coding as
described in contemporary Straussian approaches of inter-
pretive research and grounded theory (Clarke 2005; Char-
maz 2006). A coding structure was created with the
technical support of a qualitative data analysis software.
Categories and codes were set both inductively (from the
empirical material) and deductively (from prior studies and
the topic guide) and were amended with commentarial
information in order to reach higher reliability and data-
richness. The main categories addressed (1) the perceived
implications of emerging biotechnologies, (2) the strategies
and expectations expressed by the participants, (3) the
group dynamics and discursive elements (such as approval,
rejection, speech flows, etc.) and finally (4) the different
cases the participants listed and referred to in a content-
related way. As concluding steps, the relation between the
different cases and categories were explored in depth. The
findings were summarised and prepared in memos that










Mean average age 39
Highest (current) education level
0–1 first stage basic education 4
2 lower secondary or second stage of basic education 6
3 upper secondary education 18
4 post-secondary non-tertiary education 6
5–6 tertiary education 35
Employment status
Employed or freelance 25
Retired 18
In education 18
Unemployed or unpaid work 8
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were adjusted along the whole process of the analysis. The




During the introduction to each case by the moderator,
discussants were explained what aims scientists strive for
with certain technologies such as (1) developments of
malaria drugs, (2) reduction of insect populations and (3)
bio-fuel. Overall, discussants initially expressed limited
knowledge on these cases and therefore debated on the
basis of the given information as well as former experi-
ences they collected from other fields such as science and
media. Besides critical attitudes, the discussants also ran-
domly referred to these possible benefits of SB. Benefits for
medical applications were comparably far more often
addressed than the others. 45 sections where discussants
referred to drug applications were coded, in comparison to
16 in the field of bio-fuel and only six within the field
insect population control.
The participants described the necessity for novel and
widely accessible anti-malaria drugs, sustainable bio-fuels
from renewable resources and the need for optimising the
food production. It was mostly debated how and whether
these new approaches and techniques would lead to the
anticipated aims. Those groups whose members had higher
educational levels referred much more often to benefits of
research in comparison to those people with a lower edu-
cational level. With the latter, drawbacks were given higher
priority in the discussions.
However, with all groups, benefits were almost always
negotiated along with anticipated risks and ‘negative
implications’. These imagined drawbacks often included
wide impacts such as environmental hazards or noxious
side effects. The participants also referred to the usage of
certain practices, which they considered as being morally
wrong, as for instance the unavailability of drugs for cer-
tain population groups or the monopolisation of financial
gains. A general understanding of the necessity of research
was however given during the group discussions, albeit
being paired with a critical stance and an awareness for
alternative approaches.
In particular with the topics synthetic algae (coded 33
times) and synthetic viruses (coded 17 times), people
questioned the necessity of SB for achieving certain ben-
efits. Solely when people referred to drug applications this
discourse was not prevalent (coded 6 times). The groups
typically found consensus on a certain problem like
increasing fuel demands but at the same time questioned
whether high risk technologies were the preferable solu-
tion. On account of this, people discussed how renewable
energy sources, mixed crop cultivation or abstemious
lifestyles might be better solutions.
The following example 1 demonstrates how groups
typically negotiated benefits and associated risks.
Example 1: Erlangen, 18–35 years old, higher education
level
T4: Malaria is indeed a huge problem in Africa and
South-Asia (…) therefore I find this research very
important, essential (…). You cannot discuss it ethi-
cally because there are no embryonic stem cells in
use.
T1: This sounds promising, however, I would be
careful to legitimate this kind of research with solu-
tions to social and medical issues in developing
countries (…) because I do not see the problem with
the amount of malaria drugs (…), but with the
distribution.
T7: But how do you want to fight malaria? I mean
you have to develop a drug (…).
T1: True, I would agree but I think there are already
enough drugs for malaria. The problem is that those
people who really need them often lack access due to
patents, due to economic dependencies.
T8: Of course not, but with a delay of the typical
20 years indeed. This is of course a long time (…),
but the hope is that it helps those people in 20 years.
T3: Maybe! For me it matters how these drugs get
used (…). It would be a pity if it, again, would be
intended for Europeans only.
T5: I cannot imagine that those who do research on
this drug think about helping the 3rd World. I think
that they do research for earning money.
The selected unit starts with the framing of malaria as a
serious problem in Southern parts of the world and the
conclusion that research should be conducted. It is followed
by a justification that this sort of research is ethically valid in
comparison to other approaches like stem cell research. The
next argument stresses suspiciousness and the reassessing of
the necessity of this approach (merely a distribution issue).
Right afterwards benefits (medication) are brought up again
as a supportive argument for this sort of research. The
response condenses the argument of distribution to questions
of access and monopolisation. Another respondent acknowl-
edges the criticism but directly addresses the long term
redemption. The statement is followed by another argument
that criticises the uneven global distribution. The unit then
closes with questioning the integrity of those people who
conduct research and their intentions for the common good.
This first example shows how single topics were inter-
woven and negotiated along other issues. Questions of
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benefits were strongly linked to distribution and its gov-
ernance. The next section will address these questions in
more detail.
Distribution
Discourse addressing commercial interests and monopolies
was randomly present during the focus group sessions.
Most groups found consensus on the issue that the output of
this sort of research promise great economic value and
therefore wondered about how gains and benefits were
distributed. The participants debated the role of corpora-
tions and Western societies and how these entities capi-
talise power and resources. Many discussants expressed the
feeling that there is invisible correlation between having
the lead with science and its research programs and results
of research and an economic reasoning, which is embedded
as an important but in transparent driver of research.
The dominant discourse on distribution was not directed
towards rejecting biotechnologies, but towards creating the
awareness of doing things ‘‘the right way’’. The respective
examples used were either companies or corporations that
capitalise financial gains from drug or fuel production, or
the ‘‘West’’ taking advantage of the ‘‘Global South’’.
Even though the subject matter of just distribution was
indeed a topic of great relevance to all groups, there were
large differences between the different areas of SB-appli-
cation. Codes that address distribution, monopolisation, or
patenting issues were coded 53 times with the case of
synthetic fungus/drug, and comparably much less fre-
quently with algae/bio-fuel (23 times) or virus/agriculture
(12 times). However, it must be considered, that this
imbalance was also triggered by the usage of a case that
included malaria, a disease, which typically occurs in
Southern countries and therefore enhanced discussions
about global justice.
Another noticeable difference was demonstrated by the
educational level of the groups. Whereas those groups with
discussants with higher education reflected more on global
distributional justice, fairness and monopolisation in gen-
eral, the lower-educated groups did oppose economic
interests of corporations more often. The groups with
higher education typically prone to ask if certain groups
(e.g. Global South) were excluded from research benefits.
The strong discourse on a democratisation of risks and
benefits showed how research and its products were asso-
ciated with wider consequences and impacts.
Systemic and process-oriented understandings
Regardless if the groups discussed benefits, distribution or
other related risks, a sensitiveness to interrelations and
consequences could be observed. It could be seen that risks
were in many cases not directly addressed in an essentialist
way towards the products of science itself (such as a syn-
thetic drug or synthetic virus) but rather to its anticipated
impacts and indirect implications on existing systems.
Influencing or controlling possible impacts was mostly
debated on the level of expert-regulation and technical or
legal solutions.
In the case of synthetic fungus/drug, the participants
discussed how a synthetic drug may have (no) implications
on Southern parts of the world or unknown long-term
implications on patients. Both issues address indirect
consequences and wider impacts. However, within this
example, the participants agreed that all options for con-
trolling science and its products via tests and clinical trials
should be exploited. Possibilities for control were mainly
anticipated by those groups with higher education, whereas
those groups with lower education did only seldom debate
possibilities for control and containment. With both other
examples, and in particular with the case of virus/agricul-
ture, the discussants were less optimistic about possibilities
for control.
The case of algae/bio-fuel typically triggered a discourse
on environmental impacts and the disruptions of system
balances. Likewise to the first case, the groups seldom
associated hazards with a synthetically created alga itself,
but with the wider impacts it might have. Subsequently, in
the participants’ view its release might disturb the natural
system, which is considered as being in balance. The actual
imagined impacts ranged from the replacement of other
species of algae to environmental hazards or indirect
impacts on humans if algae find their way into the food
chain—either as a dish or via seafood that was exposed to
it. In addition it was assumed that a synthetic alga may be
subject to evolutionary processes. The prevalent option of
containment was considered as a containment of algae in
closed tanks.
The case of virus/agriculture was debated with the
highest level of anxiety. Concerns about the unleashing and
irreversible consequences were dominant during the dis-
cussions. These concerns were even strengthened by the
shared understanding that a virus may always mutate, even
if designed to stay stable. People thereby referred to
examples from the media, such as movies on epidemics, as
well as to knowledge about flu viruses that alter each year.
The anticipated impacts ranged from invasive effects on
humans to environmental hazards and disruptions of insect
populations. All groups spotted limited options for con-
trolling or containing a synthetically created virus.
The products of emerging biotechnologies were discur-
sively processed in a systemic understanding of nature,
science and technology, rather than on the base of their
ontological status. The groups thereby followed a causal
rather than an essentialist approach. This means that the
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causes and effects, and in particular the indirect ones,
gained most attention in the groups’ discussions, rather
than the objects themselves in their constitution and exis-
tence. Special unease could be noted regarding the idea that
the hybrid objects of science get unleashed and embedded
into the world. The following example 2 demonstrates how
the case of a virus triggered particular concerns in relation
to a drug based on synthetic ingredients.
Example 2, Vienna, 18–35 years old, lower educational
level
T1: You cannot make tests in the outside world. You
cannot say how warm it is, how much wind there is,
how fast it will spread.
T3: I understand, (…) there are other conditions out
there, but I do not think that they are fully
controllable.
T5: But I think that drugs, I mean, there is a human
attached, the consumer. (…) but what is outside
cannot be influenced completely, cannot be con-
trolled. And yes, the drug is by then finished, a fin-
ished product.
T2: If the drug is harmful to the human body, you can
withdraw it, yes? But if I unleash a virus out in the
nature, what can I do then? I cannot tell him, ‘‘come
back to the lab, I made a mistake’’. It is then out there
and reproduces and spreads. You must activate
instruments against this, but those are possibly not
applicable. I think about a movie called ‘the deadly
virus’.
T5: Because a virus can alter.
T2: Right, it mutates and mutates on and they have
found a cure, but it is the wrong one, and, humans die
like flies [laughing]. If I imagine it in a corn field and
I consume bread and get something, what do I know?
And doctors have only limited knowledge; they do
not know what I am ill from (…). A virus is too
unpredictable.
T6: Yes, as long as diseases like HIV are not com-
pletely explored, one should be careful with a virus.
Because HIV is an example that viruses are
unpredictable.
The section starts with claiming that tests cannot be made
in the outside world because the conditions are not stable.
This thought is followed by the perception that drugs
cannot be controlled. T5 in turn stresses that a drug is much
closer in relation to a virus that is ‘‘out there’’. This leads to
the conclusion that the latter cannot be controlled, whereas
a drug is an isolated product. This argumentation supports
the first statement. Another participant jumps on the
bandwagon and agrees that a drug might be withdrawn
from the market, whereas an unleashed virus cannot. This
statement is backed up by some media content. T5
sharpens the discourse by referring to the possibility of
alteration—T2 directly supports this argumentation and
continues to link it with media examples. This leads to the
conclusion that even experts may not be able to help and
understand the issue, as it is unpredictable. The last
argument refers to the lack of fully understanding HIV.
This short example shows how a group of people finds a
consensus about a synthetic virus for agricultural purposes
and labels it as being uncontrollable. The described dis-
cussion represents a typical example of the limited diver-
gent opinions within this specific discourse and displays
that this perception was shared among the discussants.
However, even though this example indicated serious
concerns, there were still benefits expected concerning SB
that were balanced with the anticipated risks during the
discussion.
Discussion
The provided focus group data reveal detailed insights into
public discourses on SB and related preferences for a
governance framework. On a very general level, discus-
sants emphasised wide-ranging complexity in this field
while reflecting on the implementation of products from
science into society and environment. As far as aims of
research were appreciated, a gradual approach receptive to
questions of distribution was predominant. The ways in
which scientists aim to achieve benefits were challenged by
the discussants on a regular basis: discussants not only
debated possible risks but considered also alternative
solutions for achieving certain research aims. The observed
public views revealed both, parallels and differences to the
discourse from policy reports as well as to prior studies in
the field of public engagement.
Yet, we extracted five key aspects for a governance
framework that is respective for citizen’s views. These
aspects constitute the intersection of the presented results
and the content of the described policy reports and studies:
(a) differentiation versus generalisation, (b) technical
challenges and benefits, (c) bio-safety and bio-security,
(d) distribution, patenting and ownership, and (e) public
engagement:
(a) Differentiation versus generalisation The assumed or
envisioned area of application made a difference for the
way people evaluated SB. We have shown—as other
studies on public views did (BBSRC 2012; Kronberger
et al. 2012; Pauwels 2009)—that support of SB is mostly
expressed within the field of medical applications in
comparison with other fields. Policy reports only seldom
distinguish between areas of application within the large
field of SB and mostly provide valuations and recom-
mendations for governance on a general level. This shows
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that it might be worthy to discuss differentiations more
often. It was not only the general support of an emerging
biotechnology that varied in its intensity, but also the dif-
ferent approaches to address certain topics. Whether dis-
cussants spoke about distributional issues, benefits or risks
depended on which of the three cases was addressed. The
case of malaria, for instance, triggered intensive debates
about distribution and fairness, whereas synthetic viruses
revealed concerns about an assumed incalculability.
The age of the discussants showed almost no impact on
the way people discussed issues of SB. Comparatively, the
educational background showed indeed impact on the way
of reasoning and the topics which were set at stake. Those
groups with higher educational status named anticipated
benefits more often and perceived options for regulating
SB more likely than those groups with lower educational
levels.
(b) Technical challenges and benefits The discussants
have been confronted with anticipated benefits for each
case: a malaria drug, insect population control and bio-fuel.
We have reported a general acknowledgement of these
aims, but also a critical reflection of the methods of pro-
duction. The techniques of SB were challenged on a reg-
ular basis during the discussions, and alternative
approaches were contemplated. A typical example was to
give preference to electrically powered cars over the cre-
ation of bio-fuel. Other than in policy reports, discussants
did—due to their lacking expertise—not discuss technical
details, but showed awareness about the complexity and
risks of this SB-technology.
Complementary with previous studies in the field of
public engagement (Hart Research Associates 2013;
European Commission 2010) we have demonstrated that
citizens show either a balanced perception of risks and
benefits, or that they discuss risks as prevalent. At the same
time, previous studies suggest that in general most citizens
approve research with SB. The empirical data presented in
this article supports the observation in so far, that discus-
sants perceived both, risks and benefits. During focus group
discussions it became even evident that benefits and risks
could not be separated as they were always debated in
interrelation. As discussed in the first aspect (a), the rela-
tion of risks and benefits is not stable among time and
cases—which calls for a differentiated governance
approach.
(c) Bio-safety and bio-security Questions of bio-safety
and bio-security are a dominant topic in policy reports on
SB. Possible accidental or purposive impacts of synthetic
entities on humans, humanity or the environment are with
no doubt one major point of attention. This manifests also
in the EU-Directives that typically come up in the context
of SB, as shown in the introduction. Previous research on
public engagement showed comparable findings. During
the surveys conducted by the European Commission (2013)
and the Hart Research Associates (2013), respondents most
often chose items from the field of bio-safety and bio-
security as most prominent. Qualitative focus groups data
from the Hart Research Associates (2014) however, found
more discussion on unforeseen and unintended conse-
quences, rather than on bio-security issues. This corre-
sponds with our data.
The presented focus group data revealed that bio-safety
issues were comparably far more often topic of discussion
than bio-security issues. The data furthermore showed how
the linking and embedding of SB mattered more than their
ontological status. There were only limited reflections on
the rupturing of binary categories such as living and non-
living or nature and culture (Braun et al. 2013). People
focussed more on the processes triggered by and the
embedding of synthetic entities as well as its impacts on
humans, society and the environment. Our discussants
shared the perception of a wide-ranging complexity and
multiple interests in this field, such as by the industry or
single states. The unleashing of synthetic entities were
associated with chains of reactions that are hardly pre-
dictable. Contrasting policy reports only few reflections on
biological warfare or biosafety were found in our focus
group discussions. The issue only came up during the
debate on virus/agriculture. The groups typically switched
to other topics soon once the topics of biological warfare
and bios security were brought up, which indicates that
other issues were more important to them. Yet, it might
also result from limited information on this aspect. Either
way, the presented data suggests that citizens’ mainly
desire realistic scenarios about the implementation of SB in
society and the environment, as well about the involved
actors.
(d) Distribution, patenting and ownership Reflections on
patenting and ownership are dominant across policy reports
on SB. They refer to questions about legal ownership of
products from SB and findings of respective research. This
includes also the given possibilities to patent designed
products. The distribution of benefits among various
stakeholder is seldom addressed in reports. Likewise, pre-
vious studies on public perceptions show limited data on
these issues.
Within our focus groups, discussions about the distri-
bution of benefits were dominant over questions of legal
ownership. This was particularly visible with the case of
synthetic drugs, which triggered debates about global jus-
tice. Predominantly private companies from the pharma-
ceutical industry were believed to operate in their own
interest. Nevertheless, the involvement of private compa-
nies was also valued as necessary for the sake of financing
and the production of applicable products. This reveals a
different focus than those, which can be found in policy
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reports. Whereas legal ownership might be of utter
importance for other stakeholder, such as industry partners
or legal scholars, citizens showed less interest in this issue.
(e) Public engagement: The focus group discussants
mostly expressed limited knowledge about biotechnologies
and SB but did not raise their own information deficit as a
problem. In fact, having limited knowledge was randomly
constructed as group consensus. While these findings
match the results from the Eurobarometer (2013) on the
dichotomy between public education and engagement for
the EU-27, there were still informed debates going on.
Discussants randomly referred to the given information
about SB, experiences with other technologies and cases
from media. This way, other forms of expertise and
knowledge were constructed during the debates.
Yet, options for control and containment of emerging
biotechnologies were almost only trusted when performed
by external experts or legal entities, rather than through
individual action or personal competence. If influencing
technological developments was perceived as possible, it
was expected that the field was either regulated by legal
and technical frameworks or by experts, such as policy
makers or scientists. Bottom-up strategies, such as public
protest, were almost never mentioned by the groups. The
tenor was a somehow passive approach that may result
from the expansive character of emerging biotechnologies
and the thus perceived great level of complexity. The group
situation might have also influenced this approach as
respondents might have held back ideas about bottom up
initiatives to avoid criticism by other group members if
these control options were seen as unrealistic.
In summary, the study’s participants debated the pro-
vision of a leap of faith to science paired with a regular
option for emergency exits: a granted loan. This gover-
nance modes acknowledge the anticipated aims of research
but includes elements of (public) observation. A granted
loan is a modus initiated in response to the perception that
SB is still in the making and its (possibly irreversible)
impacts are yet still unclear. Although people might
approve scientific progress because of the expected bene-
fits, they are also aware that research is scheduled to run
long-term and that its impacts may go far further. Citizens
perceive to have little influence on this development and
thus demand technical, legal and political control mecha-
nisms that may interfere at anytime necessary. In practice
this implementation of granted loans is indeed a challenge.
It is a well-known dilemma that scientists may depend
on long-term consent for research purposes while they
cannot precisely predict the future benefits and risks of
emerging biotechnologies. Innovation does, however,
always imply a certain level of risk—and most discussants
were well fond of this. Therefore, SB was mostly appre-
ciated in principle, but scientific proceeding in the field was
expected to happen in gradual approaches. During a sym-
posium on SB Iain Gillespie of the OECD stated that ‘‘it is
important to create governance systems which are sus-
tainable, forward-looking and dynamic and which allow
innovation (…) to emerge’’ (OECD 2010, 35). Corre-
spondingly, the focus group discussants indeed stressed
that security measures may not be integrated at any price,
and must certainly account for innovation, too. Approaches
are to be found, which implement flexible elements in new
(technical) solutions that address the aimed-for social
challenges. At the same time, efforts for democratising
risks and benefits are to be strengthened on a global level
and among experts, corporations and the broader public.
While stakeholder reports indeed stress comparable
issues like arranged groups of citizens, this piece of
research indicates that many details in reports and focus
group discussions do differ. Public engagement is anymore
mandatory for the growing and altering field of emerging
biotechnologies. Particularly regarding SB the up-stream-
ing activities are yet overall underrepresented.
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